Liposomal Mitoxantrone Hydrochloride clinical trials
Also written HE071.
A product of Mitoxantrone; its studies count on that page too.
How each study uses Liposomal Mitoxantrone Hydrochloride is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Liposomal Mitoxantrone Hydrochloride studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 23 Dec 1987 · NOVANTRONE · NDA 019297 (FDA, Drugs@FDA; as Mitoxantrone)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
34 studies that test it; most in 2021 (9)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 9 |
| 2022 | 6 |
| 2023 | 5 |
| 2024 | 5 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 22 · Other 12
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (20) · The First Affiliated Hospital with Nanjing Medical University (3) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Sun Yat-sen University (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · The First Hospital of Jilin University (1) · Children's Hospital of Soochow University (1)
Often tested with
Tested in the same studies.
Vincristine (5) · Rituximab (4) · Etoposide (3) · Cyclophosphamide (3) · Irinotecan (2) · Ifosfamide (2) · Venetoclax (2) · Prednisone (2)
Related medicines
As reviewed, each with the page that says it.
- A dosage form of Mitoxantrone
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test Liposomal Mitoxantrone Hydrochloride.
- Dec 2026Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AMLNot applicable · First Affiliated Hospital Xi'an Jiaotong University
- May 2027VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCTPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
- Oct 2027Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCLNot applicable · The First Affiliated Hospital with Nanjing Medical University
Studies
Open first, then newest update. How each study uses Liposomal Mitoxantrone Hydrochloride is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 34
- Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCLNot yet recruitingNot applicableThe First Affiliated Hospital with Nanjing Medical UniversityNCT07389356Written as Rituximab+Ifosfamide+Mesna+Mitoxantrone hydrochloride liposome+EtoposideHow we know
- Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AMLNot yet recruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06758726Written as Mitoxantrone Hydrochloride Liposome combined with BU/CyHow we know
- Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AMLRecruitingPhase 2Children's Hospital of Soochow UniversityNCT06221683Written as Mitoxantrone hydrochloride liposomeHow we know
- Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.RecruitingPhase 2Yizhuo ZhangNCT06514313Written as Mitoxantrone Hydrochloride Liposome+Irinotecan+VincristineHow we know
- VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCTRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06447090Written as Mitoxantrone hydrochloride liposomeHow we know
- Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AMLNot yet recruitingNot applicableFirst Affiliated Hospital Xi'an Jiaotong UniversityNCT06385808Written as MTBF regimenHow we know
- Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)RecruitingPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05875428Written as Mitoxantrone Hydrochloride Liposome InjectionHow we know
- The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.Not yet recruitingNot applicableThe First Hospital of Jilin UniversityNCT05990985Written as Mitoxantrone hydrochloride liposome injectionHow we know
- Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingPhase 1/2Second Affiliated Hospital of Soochow UniversityNCT05857982Written as Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumabHow we know
- Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid LeukemiaRecruitingPhase 1/2Hui ZengNCT05522192Written as Mitoxantrone liposomeHow we know
- Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCLActive, not recruitingPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04668690Written as Mitoxantrone Hydrochloride Liposome InjectionHow we know
- Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)CompletedPhase 2CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT05551598Written as Mitoxantrone Hydrochloride Liposome InjectionHow we know
- Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid TumorsActive, not recruitingPhase 1Sun Yat-sen UniversityNCT05620862Written as Mitoxantrone Hydrochloride LiposomeHow we know
- A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck CancersCompletedPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04902027Written as Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)How we know
- A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian CancerTerminatedPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04718376Written as Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)How we know
- Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCLTerminatedPhase 1/2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04509466Written as Part 1: Liposomal mitoxantrone hydrochloride and PegaspargaseHow we know
- A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue SarcomaTerminatedPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04900766Written as Mitoxantrone Hydrochloride Liposome InjectionHow we know
- Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCLTerminatedPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04548700Written as Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and PrednisoneHow we know
- A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric CarcinomaTerminatedPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04718402Written as Mitoxantrone Hydrochloride Liposome, intravenous injectionHow we know
- A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast CancerTerminatedPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04927481Written as Mitoxantrone Hydrochloride Liposome InjectionHow we know
See all 34 studies that test Liposomal Mitoxantrone Hydrochloride →
Given beside what is tested · 20 — Liposomal Mitoxantrone Hydrochloride is usual care or a partner of the new treatment
- Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AMLNot yet recruitingPhase 3Ruijin HospitalNCT07735117Written as Mitoxantrone Hydrochloride LiposomeHow we know
- R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaRecruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06594640Written as Mitoxantrone Hydrochloride LiposomeHow we know
- Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AMLNot yet recruitingPhase 3The First Affiliated Hospital of Soochow UniversityNCT07486479Written as Mitoxantrone Hydrochloride LiposomeHow we know
- Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCLRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07372352Written as Mitoxantrone Hydrochloride LiposomeHow we know
- Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell LymphomaRecruitingPhase 1/2Sun Yat-sen UniversityNCT07093710Written as Mitoxantrone Hydrochloride LiposomeHow we know
- Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)Not yet recruitingPhase 1/2Sun Yat-Sen University Cancer CenterNCT07288814Written as Mitoxantrone Hydrochloride Liposome & EnlonstobartHow we know
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingPhase 2Ming-Yuan ChenNCT07070479Written as Mitoxantrone Hydrochloride LiposomeHow we know
- Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AMLRecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06621212Written as mitoxantrone hydrochloride liposomeHow we know
- JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal CancerNot yet recruitingPhase 2Shanghai JMT-Bio Inc.NCT06892431Written as Mitoxantrone Hydrochloride LiposomeHow we know
- Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPCRecruitingPhase 2Ming-Yuan ChenNCT06472713Written as Mitoxantrone hydrochloride liposome injectionHow we know
- Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AMLRecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06621199Written as Mitoxantrone hydrochloride liposomeHow we know
- Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCLRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06489808Written as Mitoxantrone hydrochloride liposomeHow we know
- Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AMLRecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06434662Written as mitoxantrone hydrochloride liposomeHow we know
- Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing TreatmentNot yet recruitingPhase 3CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT05717764Written as Mitoxantrone hydrochloride liposome injectionHow we know
- Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell LymphomaNot yet recruitingPhase 2Jianfeng ZhouNCT05575973Written as Mitoxantrone Hydrochloride LiposomeHow we know
- Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell LymphomaActive, not recruitingPhase 1/2Sun Yat-sen UniversityNCT05464433Written as Tislelizumab combined with Liposomal mitoxantrone hydrochlorideHow we know
- Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast CancerStatus unknownNot applicableCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06156761Written as Mitoxantrone hydrochloride liposomeHow we know
- A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid TumorsStatus unknownPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05344742Written as Mitoxantrone Hydrochloride Liposome injectionHow we know
- Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MMStatus unknownPhase 1CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT05052970Written as Mitoxantrone Hydrochloride Liposome injectionHow we know
- A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)Status unknownPhase 1/2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05100303Written as Mitoxantrone Hydrochloride liposome injectionHow we know